IMAGENEBIO INC (IMA) Fundamental Analysis & Valuation

NASDAQ:IMA • US45175G2075

Current stock price

5.75 USD
-0.08 (-1.37%)
At close:
5.64 USD
-0.11 (-1.91%)
After Hours:

This IMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMA Profitability Analysis

1.1 Basic Checks

  • IMA had negative earnings in the past year.
  • In the past year IMA has reported a negative cash flow from operations.
  • IMA had negative earnings in each of the past 5 years.
  • IMA had a negative operating cash flow in each of the past 5 years.
IMA Yearly Net Income VS EBIT VS OCF VS FCFIMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of IMA (-34.25%) is comparable to the rest of the industry.
  • With a Return On Equity value of -39.35%, IMA perfoms like the industry average, outperforming 58.64% of the companies in the same industry.
Industry RankSector Rank
ROA -34.25%
ROE -39.35%
ROIC N/A
ROA(3y)-34.84%
ROA(5y)-31.64%
ROE(3y)-39.53%
ROE(5y)-36.36%
ROIC(3y)N/A
ROIC(5y)N/A
IMA Yearly ROA, ROE, ROICIMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMA Yearly Profit, Operating, Gross MarginsIMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IMA Health Analysis

2.1 Basic Checks

  • IMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IMA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, IMA has less shares outstanding
  • IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMA Yearly Shares OutstandingIMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
IMA Yearly Total Debt VS Total AssetsIMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • IMA has an Altman-Z score of -0.26. This is a bad value and indicates that IMA is not financially healthy and even has some risk of bankruptcy.
  • IMA's Altman-Z score of -0.26 is in line compared to the rest of the industry. IMA outperforms 44.50% of its industry peers.
  • There is no outstanding debt for IMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.26
ROIC/WACCN/A
WACC9.61%
IMA Yearly LT Debt VS Equity VS FCFIMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IMA has a Current Ratio of 12.49. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 12.49, IMA belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
  • IMA has a Quick Ratio of 12.49. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of IMA (12.49) is better than 82.72% of its industry peers.
Industry RankSector Rank
Current Ratio 12.49
Quick Ratio 12.49
IMA Yearly Current Assets VS Current LiabilitesIMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IMA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.51% over the past year.
  • IMA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -38.63% yearly.
EPS 1Y (TTM)40.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.72%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-62.86%
Revenue growth 5Y-38.63%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, IMA will show a small growth in Earnings Per Share. The EPS will grow by 3.42% on average per year.
  • IMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 138.32% yearly.
EPS Next Y73.61%
EPS Next 2Y28.79%
EPS Next 3Y15.74%
EPS Next 5Y3.42%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.32%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMA Yearly Revenue VS EstimatesIMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2030 2031 2032 2033 100M 200M 300M
IMA Yearly EPS VS EstimatesIMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMA Valuation Analysis

4.1 Price/Earnings Ratio

  • IMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMA Price Earnings VS Forward Price EarningsIMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMA Per share dataIMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMA's earnings are expected to grow with 15.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.79%
EPS Next 3Y15.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMA Dividend Analysis

5.1 Amount

  • No dividends for IMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMA Fundamentals: All Metrics, Ratios and Statistics

IMAGENEBIO INC

NASDAQ:IMA (4/28/2026, 5:37:53 PM)

After market: 5.64 -0.11 (-1.91%)

5.75

-0.08 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10
Earnings (Next)05-06
Inst Owners40.99%
Inst Owner Change-0.01%
Ins Owners4.7%
Ins Owner Change36.28%
Market Cap61.24M
Revenue(TTM)800.00K
Net Income(TTM)-52.40M
Analysts77.14
Price Target16.32 (183.83%)
Short Float %7.29%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-61.14%
Min EPS beat(2)-125.09%
Max EPS beat(2)2.82%
EPS beat(4)3
Avg EPS beat(4)-12.39%
Min EPS beat(4)-125.09%
Max EPS beat(4)57.57%
EPS beat(8)7
Avg EPS beat(8)1.81%
EPS beat(12)10
Avg EPS beat(12)3.27%
EPS beat(16)12
Avg EPS beat(16)2.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)49.93%
EPS NY rev (1m)41.13%
EPS NY rev (3m)41.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 76.55
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-7.21
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-4.49
FCFYN/A
OCF(TTM)-4.49
OCFYN/A
SpS0.08
BVpS12.5
TBVpS12.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -34.25%
ROE -39.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.84%
ROA(5y)-31.64%
ROE(3y)-39.53%
ROE(5y)-36.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.49
Quick Ratio 12.49
Altman-Z -0.26
F-Score6
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.72%
EPS Next Y73.61%
EPS Next 2Y28.79%
EPS Next 3Y15.74%
EPS Next 5Y3.42%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-62.86%
Revenue growth 5Y-38.63%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.32%
EBIT growth 1Y11.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4%
OCF growth 3YN/A
OCF growth 5YN/A

IMAGENEBIO INC / IMA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IMAGENEBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMA.


Can you provide the valuation status for IMAGENEBIO INC?

ChartMill assigns a valuation rating of 0 / 10 to IMAGENEBIO INC (IMA). This can be considered as Overvalued.


Can you provide the profitability details for IMAGENEBIO INC?

IMAGENEBIO INC (IMA) has a profitability rating of 1 / 10.


What is the financial health of IMAGENEBIO INC (IMA) stock?

The financial health rating of IMAGENEBIO INC (IMA) is 7 / 10.


What is the earnings growth outlook for IMAGENEBIO INC?

The Earnings per Share (EPS) of IMAGENEBIO INC (IMA) is expected to grow by 73.61% in the next year.